Inclusion Criteria:

- Age > 20 years

- Signed informed consent

- Histologically documented, incurable, locally advanced or metastatic cancers that
have failed to respond to at least one prior regimen or for which there is no
standard therapy.

- Disease that is measurable or evaluable by RECIST 1.1 criteria (for Solid Tumors)

- ECOG performance status 0-2

- Documented negative pregnancy test for women of childbearing potential and use of an
effective means of contraception for both men and women while enrolled in the study

- Granulocyte count ≥ 1,500/㎣, platelet count ≥ 100,000/㎣, and hemoglobin ≥ 9 g/dL

- Serum bilirubin ≤ 1.5 x upper limit of normal (ULN)(≤ 3 x ULN if liver metastatic
cancer)

- Alkline phosphatase, AST and ALT ≤ 2.5 x ULN (≤ 5 x ULN if liver metastatic cancer)

- Serum creatinine ≤ 1.5 mg/dL

- INR (international normalized ratio) ≤ 1.3, and aPTT (activated partial
thromboplastin time) ≤ 1.5 x ULN

- Subject had to have a projected life expectancy of at least 3 months

- Bazetts correction QTc < 450 msec in ECG at Screening

Exclusion Criteria:

- Less than 4 weeks since last chemotherapy (including biologic unless previous Avastin
treatment, experimental, and hormonal therapy), radiation therapy, or major surgical
procedure

- All incisions from any procedure must be fully healed and sutures removed prior to
infusion on Day 1

- Pleural effusions, ascites, or leptomeningeal disease as the only manifestation of
the current malignancy

- Subjects that have hypertension that is remained uncontrolled, despite drug regimen.

- Subjects with grade III or IV hemorrhage/bleeding and who have experienced pulmonary
hemorrhage/hemoptysis (exceed size of 2.5 mL of erythrocyte) or who have experienced
grade III/IV hemorrhage/bleeding.

- The presence of gastrointestinal perforation

- The presence of tracheoesophageal fistula or grade Ⅳ fistula

- Subjects with grade Ⅳ proteinuria (nephritic syndrome)

- The presence of arterial thromboembolic events

- Subjects who have history of life threatening (grade Ⅳ) pulmonary embolism

- Subjects with a known hypersensitivity to CHO cell product or other recombined human
or humanized antibody

- Subjects with mental illness

- Subjects with a known hypersensitivity to any of the ingredients/substrates in
investigational product of this study

- Subjects who given any investigational drug within longer period between 30 days and
5 times of half life before participation in this study

- Active infection requiring IV antibiotics

- Active autoimmune disease that is not controlled by drugs

- Clinically important history of liver disease, including viral or other active
hepatitis, current alcohol abuse, or cirrhosis

- Known human immunodeficiency virus (HIV) infection

- Any other diseases, metabolic dysfunction, physical examination finding, or clinical
laboratory finding giving reasonable suspicion of a disease or condition that
contraindicates the use of an investigational drug or that may affect the
interpretation of the results or renders the subjects at high risk from treatment
complications

- Significant traumatic injury within 3 weeks of Day 1

- Inability to comply with study and follow-up procedures